StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.82−0.10 (-1.69%)

Close on Nov 18, 2026Market cap $145.50KP/E –Yield –

AgomAb Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

For fiscal 2025 it was -€62.55M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€62.55M–
FY2024Dec 31, 2024-€46.27M–
FY2023Dec 31, 2023-€11.39M–

More AgomAb Therapeutics figures

See a number that looks wrong?